Percutaneous Transluminal Caval-flow Regulation PTCR®: An Emerging Therapy to Reduce Total Cardiac Burden in Heart Failure Patients

In this communication we want to make the scientific community aware of a new procedure called Percutaneous Transluminal Caval flow Regulation PTCR as an emerging therapy to reduce hypervolemia present in 90% of cases of AHF acute heart failure in the emergency department, this therapy Emergent is capable of producing a reduction in hypervolemia that leads to a reduction in preload, filling pressures, LV diastolic and systolic diameters, producing remodeling reversal and total cardiac load. Also producing a marked reduction in pulmonary congestion, this procedure is minimally invasive and so far no contralateral effects have been reported.